Top Story

FDA approves first biosimilar product

March 6, 2015

The FDA today announced the approval of filgrastim-sndz, the first biosimilar product approved in the United States.

“Biosimilars will provide access to important therapies for patients who need them,” Margaret A. Hamburg, MD, FDA commissioner, said in a press release. “Patients and the health care community can be confident that biosimilar products approved by the FDA meet the agency’s rigorous safety, efficacy and quality standards.”

In the Journals

Hospital type, patient age influence treatment of newly diagnosed myelodysplastic syndrome

March 6, 2015
Patients treated for recently diagnosed myelodysplastic syndrome at major academic institutions received more aggressive treatment than those treated at community…
In the Journals

Mohs micrographic surgery may effectively treat rare hidradenocarcinoma

March 5, 2015
Mohs micrographic surgery was an effective long-term treatment for patients with hidradenocarcinoma, according to study results.Researchers retrospectively evaluated the…
In the Journals

Patient characteristics linked to degree of family involvement in treatment decisions

March 5, 2015
A majority of patients recently diagnosed with lung or colorectal cancers chose to include family members in treatment-related decisions, according to study…
In the Journals

ADT increases risk for cardiovascular disease in men with prostate cancer

March 5, 2015
Patients with prostate cancer who received androgen-deprivation therapy demonstrated an increased risk for cardiovascular disease, according to study results.Men with a…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Video
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan